Company Overview of Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA discovers and develops of drugs for the treatment of ocular diseases. It provides FOV1101/Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age related macular degeneration. The company was founded in 2005 and is based in Paris, France. As of October 30, 2009, Fovea Pharmaceuticals SA operates as a subsidiary of Sanofi.
Institut de la Vision
17 rue Moreau
Founded in 2005
33 1 44 16 42 42
33 1 44 16 42 40
Key Executives for Fovea Pharmaceuticals SA
Similar Private Companies By Industry
|Schering-Plough S.A. (France)||Europe|
|Merck Serono s.a.s.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Fovea Pharmaceuticals SA, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.